Another imminent problem is that the GLP-1RAs that are currently used in the clinical setting are biological macromolecular peptide preparations, such as exenatide and liraglutide, with high production costs that limit their clinical application (231)
Food intake, hydration, fiber, activity, other medications, and baseline bowel habits may all be relevant
One possibility is dehydration
GLP-1, alongside PYY (Peptide YY), increases satiety levels
My solution to this problem was simple: 1 shot of 2.5-5 mg of Tirzepatide weekly combined with 1 shot of Retatrutide at 2-4 mg weekly By leveraging the appetite-suppressing effects of Tirzepatide to eliminate cravings and hunger, I was able to get the best of both worlds simultaneously
Through downregulating monocyte chemoattractant protein-1 expression, semaglutide treatment, an FDA-approved GLP-1 RA medicine targeting Type II diabetes mellitus (T2DM) (Christou et al., 2019), inhibited monocyte migration and infiltration from the circulatory system to inflammatory regions (Pontes-da-Silva et al., 2022)
:max_bytes(150000):strip_icc()/ozempic-GettyImages-2171479933-070be1d0cc1e4dcc9681c3eaa69497d0.jpg)
